Skip to Content

Fidelity® Select Biotechnology FBIOX Fund Analysis

| Quantitative rating as of

Morningstar’s Analysis FBIOX

Will FBIOX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.



A decline in its Process Pillar rating is the primary driver of Fidelity® Select Biotechnology's downgrade to a Morningstar Quantitative Rating of Neutral from Bronze. The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Unlock our full analysis with Morningstar Investor